Read more
A comprehensive review of the recent developments in DNA repair research that have potential for translational applications. The book explains in detail the various biological mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK. The book captures-for both cancer researchers and oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.
List of contents
Preface.- Repair of DNA Interstrand Cross-links Produced by Cancer Chemotherapeutic Drugs.- DNA-PK, a pharmacological target in cancer chemotherapy and
radiotherapy?.- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses.- The relationship between DNA-repair genes, cellular radiosensitivity and the response of tumors and normal tissues to radiotherapy.- Important Roles of ERCC1 in DNA Repair and Targeted Therapy.- The role of BRCA1 and BRCA2 in anticancer drug therapy.- DNA-PK in CLL Chemotherapy.- Poly(ADP) ribose polymerase at the interface of DNA damage signalling and DNA repair.- Cellular protection against the antitumor drug bleomycin.- ATR as a Therapeutic Target.- Telomeres, Telomerase and DNA Damage Response in Cancer Therapy.- RAD51 is a key protein of DNA repair and homologous recombination in humans.- Index.
Summary
A comprehensive review of the recent developments in DNA repair research that have potential for translational applications. The book explains in detail the various biological mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK. The book captures-for both cancer researchers and oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.
